Skyrizi, illustration of injection pen form (not a photo of the actual pack)

Illustrative image.

Skyrizi

Risankizumab

Prescription required

$3867.00

600mg · 1 vial

BrandBranded medicine· By Abbvie

Strength

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

150mg/mL

360mg/2.4mL

600mg

About Skyrizi

Overview

Skyrizi contains risankizumab, a monoclonal antibody medicine. It treats moderate-to-severe plaque psoriasis in adults and children aged 6 years and older who are candidates for systemic treatment or light therapy, and active psoriatic arthritis in the same age groups. It also treats moderately to severely active Crohn’s disease and ulcerative colitis in adults. It works by blocking IL-23, a protein involved in immune responses, and reducing the release of substances that promote inflammation.

What it treats

- Moderate-to-severe plaque psoriasis in adults and children aged 6 years and older who are candidates for systemic treatment or phototherapy. - Active psoriatic arthritis in adults and children aged 6 years and older. - Moderately to severely active Crohn’s disease in adults. - Moderately to severely active ulcerative colitis in adults.

Safety information

Side effects

Common side effects vary by the condition being treated and the treatment phase: For plaque psoriasis and psoriatic arthritis: upper respiratory infections, headache, tiredness, reactions at the injection site and fungal skin infections (tinea). For Crohn’s disease: upper respiratory infections, headache and joint pain during initial treatment. During maintenance treatment, common effects include joint pain, abdominal pain, injection site reactions, anemia, fever, back pain, joint problems and urinary tract infections. For ulcerative colitis: joint pain during initial treatment. During maintenance treatment, common effects include joint pain, fever, injection site reactions and rash. Serious allergic reactions, including anaphylaxis, may occur and require urgent medical attention. Skyrizi may increase the risk of infection. Contact a doctor if signs or symptoms of a significant infection occur; Skyrizi should not be given until the infection resolves. Drug-induced liver injury has been reported during initial treatment for inflammatory bowel disease. Liver enzymes and bilirubin must be monitored before treatment, during initial treatment through at least 12 weeks, and afterwards as part of routine care. Contact your doctor if liver injury is suspected.

When to call your doctor

• Seek immediate medical attention for a serious allergic reaction (anaphylaxis). • Seek medical advice promptly if you develop signs of infection, such as fever.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use Skyrizi if you have had a serious allergic reaction to risankizumab or any of its other ingredients. Serious allergic reactions, including anaphylaxis, may occur. Skyrizi may increase the risk of infection. Seek medical advice if you develop signs or symptoms of a significant infection. If one develops, Skyrizi should not be given until the infection has resolved. You should be evaluated for tuberculosis (TB) before starting treatment. Liver injury has been reported during initial treatment for inflammatory bowel disease. Liver enzymes and bilirubin should be checked before treatment and monitored during initial treatment for at least 12 weeks, then as part of routine care. Avoid live vaccines during treatment.

Interactions

Tell your doctor about all medicines, vitamins, herbal products and supplements you take, especially other biologic treatments or medicines that suppress the immune system. Combining immune-suppressing treatments may increase the risk of infection. Avoid live vaccines during Skyrizi treatment. Check with your doctor before any vaccination, as some vaccines may need to be given before treatment begins. No specific food interactions are well established.

Using Skyrizi

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use and how long it may be kept at room temperature afterwards. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label SKYRIZI (RISANKIZUMAB-RZAA) KIT SKYRIZI (RISANKIZUMAB-RZAA) INJECTION SKYRIZI (RISANKIZUMAB-RZAA) INJECTION, SOLUTION [ABBVIE INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines